How much does a one-year course of Larotinib/Larotinib cost?

Larotrectinib is a targeted therapy targeting the NTRK fusion gene and has been approved for the treatment of a variety of tumors carrying NTRK fusion genes, including patients with locally advanced and metastatic cancer. The drug's efficacy has been demonstrated in multiple clinical studies and provides an effective treatment option, especially for patients who are refractory to other treatments or have failed previous treatments. However, due to the specificity of its targeted therapy and expensive production costs, the cost of larotrectinib treatment is relatively high, which has become an important factor that patients need to consider when choosing a treatment option.

For adult patients, the recommended dose of larotrectinib is usually 100 mg taken orally twice daily until disease progression or the drug's side effects become unacceptable. At this dose, patients need to take approximately 60 100 mg larotrectinib capsules per month. The specifications of larotrectinib on the market are 100 mg/tablet and 56 pills per bottle. Therefore, the dosage of each bottle is enough for patients to take it for about half a month. According to current domestic market information, a bottle of 100 mg x 56 capsules of larotrectinib capsules is priced at about 20,000 yuan. It can be seen that the cost of larotinib treatment is indeed a considerable financial burden for patients who use it for a long time.

Based on this price, if the patient takes the recommended dose every day, the annual treatment cost of larotrectinib is roughly several hundred thousand yuan. This cost can be a significant financial burden for most patients, especially if they are uninsured or have inadequate coverage.

It is worth noting that the length of larotrectinib treatment depends on the patient’s disease progression and tolerance to the drug. In some patients, larotrectinib may be effective for a few months or around a year, while for some resistant patients, treatment may need to be adjusted or changed. Although larotrectinib has shown good efficacy in the treatment of NTRK fusion gene-positive tumors, its expensive drug cost is still a practical problem that cannot be ignored during the treatment process.

Reference materials:https://www.vitrakvi.com/